Adverse cutaneous effects of psychotropic medications

References

• Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J. Clin. Psychiatry 60(10), 714–25 (1999).
   PubMedGoogle Scholar
• Levenson JL. Psychiatric issues in dermatology, part 3: acne vulgaris and chronic idiopathic pruritus. Primary Psychiatry 15(12), 28–30 (2008).
   Google Scholar
• Murak-Kozanecka E, Rabe-Jabłońska J. Prevalence and type of dermatologic disorders in psychiatric patients treated with psychotropic drugs. Psychiatr Pol. 38(3), 491–505 (2004).
   PubMedGoogle Scholar
• Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel RR, Rüther E, Cordes J. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J. Clin. Psychiatry 70(9), 1258–1265 (2009).
   PubMedGoogle Scholar
• Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am. J. Clin. Dermatol. 3, 629–636 (2002).
   PubMedGoogle Scholar
• Degner D, Grohmann R, Kropp S et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 37( Suppl. 37), S39–S45 (2004).
   PubMedGoogle Scholar
• Milionis HJ, Skopelitou A, Elisaf MS. Hypersensitivity syndrome caused by amitriptyline administration. Postgrad Med. J. 76, 361–363 (2000).
   PubMedGoogle Scholar
• Margolis HC, Chounard G, Beauclair L. Cutaneous vasculitis induced by paroxetine. Am. J. Psychiatry 158, 497–8 (2001).
   Google Scholar
• Warnock JK, Morris DW. Adverse cutaneous reaction to antidepressants. Am. J. Clin. Dermatol. 3, 329–39 (2002).
   PubMedGoogle Scholar
• Martin T, Li H. Severe cutaneous adverse drug reactions: a review on epidemiology, etiology, clinical manifestation and pathogenesis. Chin. Med. J. (Engl.) 121(8), 756–61 (2008).
   PubMed Web of Science ®Google Scholar
• Song YO, Lee JI, Chang AK, Kang SH. Two Cases of Reversible Skin Rash Associated with Quetiapine-Valproate C ombination Treatment. Korean J. Psychopharmacol. 22(3), 154–156 (2011).
   Google Scholar
• Gupta MA, Levenson JL. Dermatology. In: American Psychiatric Publishing Textbook of Psychosomatic Medicine. Levenson JL ( Ed.). American Psychiatric Publishing, Washington DC, USA, 667–690 (2011).
   Google Scholar
• Sehgal VN. Textbook of Clinical Dermatology (4th Edition). Sehgal VN ( Ed.). Jypee Brothers Medical Publishers, New Delhi, India, Chapter 1, 1–9 (2006).
   Google Scholar
• Cederberg J, Knight S, Svenson S, Melhus H. Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report. BMC Psychiatry 4, 36 (2004).
   PubMedGoogle Scholar
• Ständer S, Böckenholt B, Schürmeyer-Horst F et al. Treatment of chronic pruritus with the selectiveserotonin re-uptakeinhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm. Venereol. 89(1), 45–51 (2009).
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45(3), 666–674 (2007).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associatedpruritus. Blood 99(7), 2627 (2002).
   PubMed Web of Science ®Google Scholar
• Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J. Am. Acad. Dermatol. 50(6), 889–891 (2004).
   PubMed Web of Science ®Google Scholar
• Mishra B, Saddichha S, Kumar R, Akhtar S. Risperidone-induced recurrent giant urticaria. Br. J. Clin. Pharmacol. 64(4), 558–559 (2007).
   PubMedGoogle Scholar
• Yasharpour MR, Randhawa I. Antidepressants in chronic idiopathic urticaria. Allergy Asthma Proc. 32(6), 419–424 (2011).
   PubMedGoogle Scholar
• Welsh JP, Cusack CA, Ko C. Urticarial vasculitis secondary to paroxetine. J. Drugs Dermatol. 5(10), 1012–1014 (2006).
   PubMedGoogle Scholar
• Gallelli L, De Fazio S, Corace E, De Sarro G, Garcia CS, De Fazio P. Generalised urticaria in a young woman treated with clomipramine and after ingestion of codfish. Pharmacopsychiatry 39(4), 154–156 (2006).
   PubMedGoogle Scholar
• Karimpour H, Karimpour S, Zamani MJ et al. Toxic reactions to chronic use of benzodiazepines: An overview. Inter. J. Pharmacol. 1 (4), 376–382 (2005).
   Google Scholar
• Chang HY, Ridky TW, Kimball AB, Hughes E, Oro AE. Eruptive xanthomas associated with olanzapine use. Arch. Dermatol. 139(8), 1045–1048 (2003).
   PubMedGoogle Scholar
• Bosonnet S, Dandurand M, Moati L, Guillot B. Acute generalized exanthematic pustulosis after intake of clozapine (leponex). First case. Ann. Dermatol. Venereol. 124(8), 547–548 (1997).
   PubMedGoogle Scholar
• Mera MT, Pérez BV, Fernández RO, Iglesias JF. Hypersensitivity to paroxetine. Allergol. Immunopathol. (Madr) 34(3), 125–126 (2006).
   PubMedGoogle Scholar
• Warnock JK, Morris DW. Adverse cutaneous reactions to mood stabilizers. Am. J. Clin. Dermatol. 4(1), 21–30 (2003).
   PubMedGoogle Scholar
• Garenfeld W, Wilting I. Oculotoxic and dermatotoxic side effects of phenothiazines. Tijdschr. Psychiatr. 49(4), 251–255 (2007).
   PubMedGoogle Scholar
• Adams CE, Rathbone J, Thornley B et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Med. 3, 15 (2005).
   PubMed Web of Science ®Google Scholar
• García C, Piñero L, Oyola R, Arce R. Photodegradation of 2-chloro substituted phenothiazines in alcohols. Photochem. Photobiol. 85(1), 160–170 (2009).
   PubMedGoogle Scholar
• Almond DS, Rhodes LE, Pirmohamed M. Risperidone-induced photosensitivity. Postgrad Med. J. 74(870), 252–253 (1998).
   PubMedGoogle Scholar
• Greiner AC, Berry K.. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can. Med. Assoc. J. 90, 663–665 (1964).
   PubMed Web of Science ®Google Scholar
• Jhirwal OP, Parsad D, Basu D. Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent. Int. J. Dermatol. 43(10), 778–779 (2004).
   PubMedGoogle Scholar
• Milionis HJ, Skopelitou A, Elisaf MS. Hypersensitivity syndrome caused by amitriptyline administration. Postgrad. Med. J. 76, 361–363 (2000).
   PubMedGoogle Scholar
• Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann. Clin. Psychiatry 12(1), 35–42 (2000).
   PubMedGoogle Scholar
• Castro-Gago M, Gómez-Lado C, Eirís-Puñal J et al. Serum biotinidase activity in children treated with valproic acid and carbamazepine. J. Child Neurol. 25(1), 32–35 (2010).
   PubMedGoogle Scholar
• Patrizi A, Savoia F, Negosanti F et al. Telogen effluvium caused by magnesium valproate and lamotrigine. Acta Derm. Venereol. 85(1), 77–78 (2005).
   PubMedGoogle Scholar
• Uehlinger C, Barrelet L, Touabi M, Baumann P. Alopecia and mood stabilizers: two case reports. Eur. Arch. Psychiatry Clin. Neurosci. 242(2–3), 85–88 (1992).
   PubMedGoogle Scholar
• Yilmaz Y, Tasdemir HA, Paksu MS. The influence of valproic acid treatment on hair and serum zinc levels and serum biotinidase activity. Eur. J. Paediatr. Neurol. 13(5), 439–443 (2009).
   PubMed Web of Science ®Google Scholar
• Lee SH, Yoon J, Shin SH et al. Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS ONE 7(4), e34152 (2012).
   PubMed Web of Science ®Google Scholar
• Chan HH, Wing Y, Su R, Van Krevel C, Lee S. A control study of the cutaneous side effects of chronic lithium therapy. J. Affect. Disord. 57(1–3), 107–113 (2000).
   PubMed Web of Science ®Google Scholar
• McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379(9817), 721–728 (2012).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J. Dtsch. Dermatol. Ges. 7(2), 142–160 (2009).
   PubMed Web of Science ®Google Scholar
• Gau SS, Chao PF, Lin YJ, Chang CJ, Gau CS. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. J. Clin. Psychopharmacol. 28(5), 509–517 (2008).
   PubMedGoogle Scholar
• Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128(1), 35–44 (2008).
   PubMed Web of Science ®Google Scholar
• Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine--the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J. Dermatol. Venereol. Leprol. 71(5), 325–328 (2005).
   PubMedGoogle Scholar
• Shorter Oxford Textbook of Psychiatry (5^th edition). Gelder M, Harrison P, Cowen P ( Eds). Oxford University Press, Oxford, UK, chapter 21, 517–476 (2006).
   Google Scholar
• Taylor D, Paton C, Kerwin R. The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust. Prescribing Guidelines (Volume 9). Informa Healthcare, London, UK (2007).
   Google Scholar
• P-Codrea S, Sidenius P, Dam M. Lamotrigine-induced rash–Worth a rechallenge. Acta Neurol. Scand 111, 191–194 (2005).
   PubMedGoogle Scholar
• Desarkar P, Nizamie SH. Risperidone-induced erythema multiforme minor. Br. J. Clin. Pharmacol. 62(4), 504–505 (2006).
   PubMed Web of Science ®Google Scholar
• Upadhyaya SK, Raina RS, Sharma A, Thawani V, Dimari D. Carbamazepine-induced erythema multiforme major in an epileptic patient with bipolar affective disorder. J. Pharmacol. Pharmacother. 3(2), 202–204 (2012).
   PubMedGoogle Scholar
• Suresh Kumar PN, Thomas B, Kumar K, Kumar S. Stevens-Johnson syndrome-toxic epidermal necrolysis (SJS-TEN) overlap associated with carbamazepine use. Indian J. Psychiatry 47(2), 121–123 (2005).
   PubMedGoogle Scholar
• Huang LY, Liao WC, Chiou CC, Lou JP, Hu P, Ko FC. Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced Stevens-Johnson syndrome. J. Formos. Med. Assoc. 106(12), 1032–1037 (2007).
   PubMedGoogle Scholar
• Huang HT, Chang CL, Tzeng DS. Toxic epidermal necrolysis after sun-exposure probably due to lamotrigine and chlorpromazine. Asian J. Psychiatr. 3(4), 240–242 (2010).
   PubMedGoogle Scholar
• Kumar A, Sarkar S, Praharaj SK, Akhtar S, Diwakar M. Stevens-Johnson syndromeprogressing to toxic epidermal necrolysis with haloperidol and carbamazepine combination. Ind. Psychiatry J. 20(2), 131–133 (2011).
   PubMedGoogle Scholar
• Warnock CA, Azadian AG. Cross-sensitivity between paroxetine and sertraline. Ann. Pharmacother. 36(4), 631–633 (2002).
   PubMedGoogle Scholar
• Khairkar PH, Bang GM, Singh AB, Tiple PG. Possible cross-sensitivity between sertraline and paroxetine in a panic disorder patient. Indian J. Pharmacol. 42(2), 110–111 (2010).
   PubMedGoogle Scholar
• Fleming P, Marik PE. The DRESS syndrome: the great clinical mimicker. Pharmacotherapy 31(3), 332 (2011).
   PubMedGoogle Scholar
• Kumari R, Timshina DK, Thappa DM. Drug hypersensitivity syndrome. Indian J. Dermatol. Venereol. Leprol. 77, 7–15 (2011).
   PubMed Web of Science ®Google Scholar
• Pereira de Silva N, Piquioni P, Kochen S, Saidon P. Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs. Eur. J. Clin. Pharmacol. 67(5), 463–470 (2011).
   PubMed Web of Science ®Google Scholar
• Ganeva M, Gancheva T, Lazarova R et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int. J. Dermatol. 47, 853–860 (2008).
   PubMedGoogle Scholar
• Syn WK, Naisbitt DJ, Holt AP, Pirmohamed M, Mutimer DJ. Carbamazepine-induced acute liver failure as part of the DRESS syndrome. Int. J. Clin. Pract. 59(8), 988–991 (2005).
   PubMedGoogle Scholar
• Bosdure E, Cano A, Roquelaure B et al. Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure. Arch. Pediatr. 11(9), 1073–1077 (2004).
   PubMedGoogle Scholar
• Amante MF, Filippini AV, Cejas N, Lendoire J, Imventarza O, Parisi C. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann. Hepatol. 8, 75–77 (2009).
   PubMed Web of Science ®Google Scholar
• Shawcross D, Auzinger G. Lamotrigine and the risk of fulminant hepatic failure. Lancet 371, 649–650 (2008).
   PubMedGoogle Scholar
• Roquin G, Peres M, Lerolle N et al. First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis. Ann. Pharmacother. 44, 1998–2000 (2010).
   PubMed Web of Science ®Google Scholar
• Amante MF, Filippini AV, Cejas N, Lendoire J, Imventarza O, Parisi C. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann. Hepatol. 8(1), 75–77 (2009).
   PubMed Web of Science ®Google Scholar
• Li LM, Russo M, O'Donoghue MF, Duncan JS, Sander JW. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq. Neuropsiquiatr. 54(1), 47–49 (1996).
   PubMed Web of Science ®Google Scholar
• Woo YS, Bahk WM, Jon DI et al. Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(7), 1147–1152 (2009).
   PubMedGoogle Scholar
• Locala JA. Current concepts in psychodermatology. Curr. Psychiatry Rep. 11, 211–218 (2009).
   PubMed Web of Science ®Google Scholar
• Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report of olanzapine-induced hypersensitive syndrome. Am. J. Med. Sci. 321, 156–158 (2001).
   PubMed Web of Science ®Google Scholar
• Bliss SA, Warnock JK. Psychiatric medications: Adverse cutaneous drug reactions. Clin. Dermatol. 31, 101–109 (2013).
   PubMedGoogle Scholar
• Mishra B, Sahoo S, Sarkar S, Akhtar S. Clozapine-induced angioneurotic edema. Gen. Hosp. Psychiatry 29(1), 78–80 (2007).
   PubMed Web of Science ®Google Scholar
• Penaskovic KM, Annamraju S, Kraus JE. Clozapine-induced allergic vasculitis. Am. J. Psychiatry 162, 1543–1542 (2005).
   PubMed Web of Science ®Google Scholar
• Jones JM, Reich KA, Raval DG. Angioedema in a 47-year-old woman with hypocomplementemic urticarial vasculitis syndrome. J. Am. Osteopath. Assoc. 112(2), 90–92 (2012).
   PubMedGoogle Scholar
• Soumya RN, Grover S, Dutt A, Gaur N. Angioneurotic edema with risperidone: a case report and review of literature. Gen. Hosp. Psychiatry 32(6), 646, e1–e3 (2010).
   PubMedGoogle Scholar
• Duggal MK, Singh A, Arunabh, Lolis JD, Guzik HJ. Olanzapine-induced vasculitis. Am. J. Geriatr. Pharmacother. 3, 21–24 (2005).
   PubMedGoogle Scholar
• Sannicandro TJ, Farrar MC, Markowitz JS. Selective serotonin reuptake inhibitor-induced rash: case report and review of the literature. Pharmacotherapy 22(4), 516–518 (2002).
   PubMedGoogle Scholar
• Mera MT, Pérez BV, Fernández RO, Iglesias JF. Hypersensitivity to paroxetine. Allergol. Immunopathol. (Madr) 34(3), 125–126 (2006).
   PubMedGoogle Scholar
• Margolese HC, Chouinard G, Beauclair L, Rubino M. Cutaneousvasculitis induced by paroxetine. Am. J. Psychiatry 158(3), 497 (2001).
   PubMedGoogle Scholar
• Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am. J. Clin. Dermatol. 5(1), 3–8 (2004).
   PubMed Web of Science ®Google Scholar
• Aithal V, Appaih P. Lithium induced hidradenitis suppurativa and acne conglobata. Indian J. Dermatol. Venereol. Leprol. 70, 307–309 (2004).
   PubMedGoogle Scholar
• Cerroni L, Fink-Puches R, El-Shabrawi-Caelen L, Soyer HP, LeBoit PE, Kerl H. Solitary skin lesions with histopathologic features of early mycosis fungoides. Am. J. Dermatopathol. 21(6), 518–524 (1999).
   PubMed Web of Science ®Google Scholar
• Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J. Drugs Dermatol. 2, 279–299 (2003).
   Google Scholar
• Ferzli GT, El-Tal Ael-K, Kibbi AG, Mikati MA. Localized morphea: a rare adverse effect of valproic acid. Pediatr. Neurol. 29(3), 253–255 (2003).
   PubMedGoogle Scholar
• Goihman-Yahr M, Leal G, Essenfeld-Yahr E. Generalized morphea: a side effect of valproate sodium? Arch. Dermatol. 116(6), 621 (1980).
   PubMedGoogle Scholar
• Adams BB, Mutasim DF. Pustular eruption induced by olanzapine, a novel antipsychotic agent. J. Am. Acad. Dermatol. 41(5 Pt 2), 851–853 (1999).
   PubMedGoogle Scholar
• Molina-Ruiz AM, Molina-Ruiz RM, Zulueta T, Barabash R, Requena L. Olanzapine-induced eccrine squamous syringometaplasia. Am. J. Dermatopathol. 34(4), 434–437 (2012).
   PubMedGoogle Scholar
• Fernández-Torres R, Almagro M, del Pozo J et al. Lichenoid drug eruption induced by olanzapine. Actas Dermosifiliogr. 99(3), 221–224 (2008).
   PubMedGoogle Scholar
• Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated? : understanding pathophysiology and clinical relevance. J. Clin. Aesthet. Dermatol. 3(1), 32–38 (2010).
   PubMedGoogle Scholar
• Jafferany M. Lithium and psoriasis: What primary care and family physicians should know. Prim Care Companion J. Clin. Psychiatry 10(6), 435–439 (2008).
   PubMedGoogle Scholar
• Kansal NK, Chawla O, Singh A, Matreja PS. The Cutaneous Adverse Effects of Lithium. J. Clin. Diagn. Res. 5(3), 570–572 (2011).
   Google Scholar
• Tüzün Y, Yardımcı G. Lithium and Psoriasis. J. Turk. Acad. Dermatol. 3(4), 93401r (2009).
   Google Scholar
• Brenner S, Golan H, Lerman Y. Psoriasiform eruption and anticonvulsant drugs. Acta Derm. Venereol. 80, 382 (2000).
   PubMed Web of Science ®Google Scholar
• Hemlock C, Rosenthal JS, Winston A. Fluoxetine-induced psoriasis. Ann. Pharmacother. 26, 211–212 (1992).
   PubMed Web of Science ®Google Scholar
• Barth JH, Baker H. Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br. J. Dermatol. 115, 629–630 (1986).
   PubMedGoogle Scholar
• Du-Thanh A, Kluger N, Bensalleh H, Guillot B. Drug-induced acneiform eruption. Am. J. Clin. Dermatol. 12(4), 233–245 (2011).
   PubMed Web of Science ®Google Scholar
• Oztas P, Aksakal AB, Oztas MO, Onder M. Severe acne with lithium. Ann. Pharmacother. 35, 961–962. (2001).
   PubMedGoogle Scholar
• Mishra B, Praharaj SK, Prakash R, Sinha VK. Aripiprazole-induced acneiform eruption. Gen. Hosp. Psychiatry 30(5), 479–481(2008).
   PubMedGoogle Scholar